Marcaine

Bupivacaine hydrochloride, the active ingredient in Marcaine, is a local anesthetic presented as a sterile injectable solution for infiltration use. It provides reversible loss of sensation for surgical procedures, infiltration anesthesia, and nerve block applications in patients requiring regional pain control. GNH USA supplies Marcaine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Marcaine is a long‑acting local anesthetic used in procedures that require regional nerve blockade or tissue infiltration. - Surgical procedures: provides extended analgesia during and after operative interventions. - Infiltration anesthesia: delivers localized numbness for minor surgeries or wound repair. - Nerve block: enables targeted nerve blockade for diagnostic or therapeutic pain management.

Adverse reactions may occur following administration of Marcaine.

Common Side Effects: - Transient tingling or numbness at the injection site. - Mild dizziness or light‑headedness. - Temporary visual disturbances. - Nausea or mild vomiting. - Localized swelling or erythema.

Serious or Rare Side Effects: - Cardiovascular toxicity such as arrhythmias or hypotension. - Central nervous system toxicity including seizures or respiratory depression. - Allergic reactions ranging from rash to anaphylaxis. - Persistent motor block or prolonged numbness. - Methemoglobinemia (rare).

When using Marcaine, consider the following safety measures. - Patient assessment: evaluate cardiac and neurological status before administration. - Dose limits: adhere to recommended maximum dose to avoid systemic toxicity. - Injection technique: use aspiration and incremental dosing to reduce intravascular injection risk. - Monitoring: observe for signs of CNS or cardiovascular adverse effects during and after the procedure. - Contraindications: avoid in patients with known hypersensitivity to amide‑type local anesthetics. - Store at controlled room temperature: keep in original container, protect from light and moisture.

Marcaine may interact with other agents that affect cardiac or neurological function.

Major Interactions (Avoid): - Class I antiarrhythmic drugs (e.g., quinidine, procainamide) – may potentiate cardiotoxicity. - Beta‑blockers – can exacerbate bradycardia and hypotension. - Central nervous system depressants (e.g., opioids, benzodiazepines) – increase risk of respiratory depression.

Moderate Interactions (Monitor Closely): - Calcium channel blockers – may enhance negative inotropic effects. - Monoamine oxidase inhibitors – potential for additive CNS effects. - Other local anesthetics – cumulative toxicity risk if combined.